Acura Pharmaceuticals Stock (OTC:ACUR), Trade Ideas

Acura Pharmaceuticals

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

ACUR

ADLI

AEGN

AEIS

AGRX

ALLT

ALPP

AMED

APTV

ARES

ARNC

AROW

ASPU

ATKR

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVGOP

BANF

BASI

BIOAQ

BLDR

BWXT

CARO

CBPX

CBRE

CBSH

CCBG

CCNE

CDRL

CDUAF

CHAG

CMPR

CNOB

CNXN

CODI

CORG

CRWS

CSVI

CUBI

DNBF

DOOR

EBMT

EDTXF

ESGR

ETBI

EVER

EXPD

FBHS

FCNCA

FDEF

FITB

FLGT

FMNB

FPAY

FRTA

FULT

GABC

Stocks That Hit 52-Week Highs On Tuesday

ACGL

AFTPF

AKRFF

ANSS

APLS

ARPC

ASML

ASMLF

ASMVF

BCEKF

BCHEY

BEPTF

BF-A

BF-B

BFGIF

CACI

CARL DATA SOL INC ORD by Carl Data Solutions, Inc.

CDTAF

CHOLF

CIBEY

CNSWF

COST

COUP

CPRT

CYRTF

CYTK

DIMC

DINO

DRRX

EDHD

ESCU

ESGRP

FICO

FUNC

GNRC

GRYN

HEBT

HEMA

HNNMY

HPGLY

HTLD

IMKTA

IMOS

INFO

INGXF

IPPLF

IRET

JBSAY

KNSL

KNYJF

KNYJY

KSKGF

LDOS

LICT

LNSTY

MDCO

MEDP

MKTX

MORN

MOSC

MRBLF

MVBF

NBGIF

NGCRF

NOBH

NSRGF

Nestle Sponsored representing Registered Shares Series B

NSRGY

NTRA

NUPMF

OCPNY

OLED

OPRA

PBCTP

Stocks That Hit 52-Week Highs On Friday

Biotech

Pre-Market Outlook

ABUS

ADMP

AERI

AKRO

ALNY

ANIP

ARQL

AXSM

BCEL

BPMX

CHRS

CTRV

GLPG

KLDO

MGTX

NVTR

PRVL

PSNL

RHHBY

SGIOY

SNNA

STIM

SURF

TROV

TTPH

ZEAL

The Daily Biotech Pulse: Roche&#39;s Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

ACURA PHARMS INC by Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Inc

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals Inc

View Patent <a href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&amp;r=5101&amp;f=G&amp;l=50&amp;d=PTXT&amp;p=103&amp;S1=20211214&amp;OS=20211214&amp;RS=20211214"> Here</a>

Acura Pharmaceuticals Granted U.S. Patent #11,197,837 'Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse'

Acura Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/ACUR#NASDAQ">ACUR</a>) reported quarterly losses of $(0.15) per share. This is a 150 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $46 thousand which missed the analyst consensus estimate of $92 thousand by 50.00 percent. This is a 39.47 percent decrease over sales of $76 thousand the same period last year.

Earnings

Acura Pharmaceuticals Q2 EPS $(0.15) Down From $(0.06) YoY, Sales $46K May Not Compare To $92K Estimate

ELEEF

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.
<h3>Scaling The Peaks</h3>
(Biotech stocks hitting 52-week highs on July 2)
<ul>
<li>ANI Pharmaceuticals Inc Common Stock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>)</li>
<li>ArQule, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arql#NASDAQ">ARQL</a>)</li>
<li>Axsome Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axsm#NASDAQ">AXSM</a>)</li>
<li>Coherus Biosciences Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chrs#NASDAQ">CHRS</a>)</li>
<li>GALAPAGOS NV/S ADR (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glpg#NASDAQ">GLPG</a>)</li>
<li>MeiraGTx Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgtx#NASDAQ">MGTX</a>)</li>
<li>ZEALAND PHARMA/S ADR (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zeal#NASDAQ">ZEAL</a>)</li>
</ul>
<h3>Down In The Dumps</h3>
(Biotech stocks hitting 52-week lows on July 2)
<ul>
<li>Adamis Pharmaceuticals Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/admp#NASDAQ">ADMP</a>)</li>
<li>Aerie Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeri#NASDAQ">AERI</a>)</li>
<li>Atreca Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcel#NASDAQ">BCEL</a>)(IPOed June 20)</li>
<li>Biopharmx Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bpmx#NYSE">BPMX</a>)</li>
<li>ContraVir Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctrv#NASDAQ">CTRV</a>)</li>
<li>Kaleido Biosciences Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kldo#NASDAQ">KLDO</a>)</li>
<li>Nuvectra Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvtr#NASDAQ">NVTR</a>)</li>
<li>Personalis Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psnl#NASDAQ">PSNL</a>) (IPOed June 20)</li>
<li>Prevail Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prvl#NASDAQ">PRVL</a>) (IPOed June 20)</li>
<li>Sienna Biopharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snna#NASDAQ">SNNA</a>)</li>
<li>Surface Oncology Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/surf#NASDAQ">SURF</a>)</li>
<li>Tetraphase Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttph#NASDAQ">TTPH</a>)</li>
<li>TrovaGene Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trov#NASDAQ">TROV</a>)</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/biotech/19/07/13987454/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates">Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates</a>
<h3>Stocks In Focus</h3>
<h3>Roche&#39;s Flu Medication Found Effective And Safe In Children</h3>
Roche Holdings AG Basel ADR Common Stock (OTC: <a class="ticker" href="https://www.benzinga.com/stock/rhhby#OTC">RHHBY</a>)&#39;s Genetech unit announced its Phase 3 study dubbed MNISTONE-2 met its primary endpoint of demonstrating that Xofluza was well tolerated in children with flu. The study also showed that Xofluza is comparable to oseltamivir, a proven effective treatment, for flu in children, in reducing the duration of flu symptoms, including fever.
<h3>Glaxo-owned ViiV&#39;s 2-Drug Regimen For HIV-1 Infection Receives EU Clearance</h3>
ViiV Healthcare, majority owned by GlaxoSmithKline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsk#NYSE">GSK</a>), with Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) and SHIONOGI &amp; CO L/ADR (OTC: <a class="ticker" href="https://www.benzinga.com/stock/sgioy#OTC">SGIOY</a>) also as shareholders, said the European Commission granted Marketing Authorization for Dovato for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg.
Dovato is once-daily, single pill combination of dolutegravir and lamivudine, as opposed to the current standard of care, which is a three-drug regimen.
<h3>Acura Outlicenses Abuse Deterrent Pain Medication For Up To $21.3M</h3>
Acura Pharmaceuticals, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/acur#OTC">ACUR</a>) announced a licensing, development and commercialization agreement with Abuse Deterrent Pharma &ndash; a special purpose company representing a consortium of investors, which will finance the company&#39;s operations and completion of the development of LTX-03 immediate-release tablets using Acura&#39;s patented LIMITx technology.
The investigational drug addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse.
The transaction is valued up to $21.3 million, not including royalties. The agreement also provides for Acura receiving royalties and potential sales-related milestones and AD Pharma retaining commercialization rights.
<h3>Neuronetics Appoints Furlong as Its CFO</h3>
Neuronetics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stim#NASDAQ">STIM</a>) announced the appointment of Stephen Furlong as its CFO and Secretary, effective July 22, replacing the incumbent Peter Donato, who will leave after a transition period.
<h3>Akero Doses First Patient In Mid-Stage NASH Study</h3>
Akero Therapeutics Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) said it has begun dosing the first patient in its Phase 2a study of AKR-001, a novel FGF21 analog for the treatment of non-alcoholic steatohepatitis. The <a href="https://www.benzinga.com/news/19/06/13931028/akero-therapeutics-ipo-what-you-need-to-know"> company </a> said it will report the results of the study in the first half of 2020.
<h3>Arbutus Sells Part Of Royalty Interest In Onpattro For $20M</h3>
Arbutus Biopharma Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abus#NASDAQ">ABUS</a>) announced the sale of part of its royalty interest on future global net sales of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/07/11986010/analyst-downgrades-arbutus-biopharma-on-valuation-after">Onpattro</a>, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>), to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada, for $20 million in gross proceeds before advisory fees.

The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

Insider Trades

Form 4 Filing Out Late Tuesday Shows Acura Pharma Former 10% Owner Claudius LLC Sold ~2.196M Shares At $0.10 As Part Of Stock Purchase Agreement

Acura Pharmaceuticals Reports Q2 EPS $(0.18) vs $(0.28) In Same Period Last Year, Sales $92K vs $340K Est.

Acura Pharma Reports Initiation of Second Clinical Study on LTX-04

<ul>
<li>
		My Size, Inc. (NASDAQ: <a class="ticker" href="/stock/mysz#NASDAQ">MYSZ</a>) shares tumbled 39.3 percent to $3.89 after dropping 18.78 percent on Wednesday.</li>
<li>
		ConforMIS Inc (NASDAQ: <a class="ticker" href="/stock/cfms#NASDAQ">CFMS</a>) shares dropped 31.8 percent to $5.83 after the company posted a wider-than-expected Q4 loss.</li>
<li>
		Build-A-Bear Workshop, Inc (NYSE: <a class="ticker" href="/stock/bbw#NYSE">BBW</a>) shares dipped 29 percent to $8.45 after the company reported downbeat Q4 earnings.</li>
<li>
		Hornbeck Offshore Services, Inc. (NYSE: <a class="ticker" href="/stock/hos#NYSE">HOS</a>) shares declined 21.7 percent to $5.05. Hornbeck Offshore reported a Q4 loss of $19.2 million on revenue of $41.9 million.</li>
<li>
		Acura Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/acur#NASDAQ">ACUR</a>) dropped 19.8 percent to $0.930. Acura Pharmaceuticals disclosed that its common stock will start to trade on the OTCQB Market on February 23, 2017.</li>
<li>
		On Deck Capital Inc (NYSE: <a class="ticker" href="/stock/ondk#NYSE">ONDK</a>) shares fell 18.2 percent to $4.60 after the company posted weak Q4 earnings.</li>
<li>
		Avon Products, Inc. (NYSE: <a class="ticker" href="/stock/avp#NYSE">AVP</a>) dropped 18 percent to $4.80 after the company reported weaker-than-expected earnings for its fourth quarter.</li>
<li>
		Molina Healthcare, Inc. (NYSE: <a class="ticker" href="/stock/moh#NYSE">MOH</a>) declined 17.1 percent to $49.67. Molina Healthcare reported a Q4 loss of $91 million on revenue of $4.46 billion. Stifel Nicolaus downgraded the stock from Buy to Hold.</li>
<li>
		Cryolife Inc (NYSE: <a class="ticker" href="/stock/cry#NYSE">CRY</a>) shares dipped 16.4 percent to $16.35. Cryolife posted upbeat Q4 earnings, but sales missed expectations.</li>
<li>
		Altisource Portfolio Solutions S.A. (NASDAQ: <a class="ticker" href="/stock/asps#NASDAQ">ASPS</a>) fell 16.1 percent to $25.83. Altisource Portfolio Solutions reported a Q4 loss of $20.4 million on revenue of $227.2 million.</li>
<li>
		Syntel, Inc. (NASDAQ: <a class="ticker" href="/stock/synt#NASDAQ">SYNT</a>) shares fell 16 percent to $19.59 after the company issued a weak FY17 forecast.</li>
<li>
		PHH Corporation (NYSE: <a class="ticker" href="/stock/phh#NYSE">PHH</a>) dropped 15 percent to $12.66 after the company posted a wider-than-expected quarterly loss.</li>
<li>
		GNC Holdings Inc (NYSE: <a class="ticker" href="/stock/gnc#NYSE">GNC</a>) declined 14 percent to $7.16 after the company posted weak Q4 results.</li>
<li>
		Avis Budget Group Inc. (NASDAQ: <a class="ticker" href="/stock/car#NASDAQ">CAR</a>) shares tumbled 14 percent to $34.96 on downbeat quarterly results.</li>
<li>
		Evoke Pharma Inc (NASDAQ: <a class="ticker" href="/stock/evok#NASDAQ">EVOK</a>) fell 9.7 percent to $3.07 after the company reported a proposed public offering of common stock.</li>
<li>
		Blackhawk Network Holdings Inc (NASDAQ: <a class="ticker" href="/stock/hawk#NASDAQ">HAWK</a>) declined 9.5 percent to $33.83 on weaker-than-expected quarterly earnings. Credit Suisse downgraded Blackhawk Network from Outperform to Neutral.</li>
<li>
		MGM Resorts International (NYSE: <a class="ticker" href="/stock/mgm#NYSE">MGM</a>) dropped 7.5 percent to $27.39 after the company posted downbeat profit for the fourth quarter.</li>
<li>
		Tripadvisor Inc (NASDAQ: <a class="ticker" href="/stock/trip#NASDAQ">TRIP</a>) shares dropped 7.4 percent to $48.80 after the company posted <a href="https://www.benzinga.com/news/earnings/17/02/9055843/tripadvisor-misses-the-boat-on-earnings"> weaker-than-expected results </a> for its fourth quarter.</li>
<li>
		SunPower Corporation (NASDAQ: <a class="ticker" href="/stock/spwr#NASDAQ">SPWR</a>) shares declined 6.5 percent to $6.78 after the company reported a wider-than-expected quarterly loss.</li>
<li>
		Mazor Robotics Ltd - ADR (NASDAQ: <a class="ticker" href="/stock/mzor#NASDAQ">MZOR</a>) fell 5.4 percent to $22.15. Mazor Robotics reported a Q4 loss of $0.07 per share on revenue of $14.043 million.</li>
<li>
		NGL Energy Partners LP (NYSE: <a class="ticker" href="/stock/ngl#NYSE">NGL</a>) dropped 4.2 percent to $23.15. NGL Energy Partners priced its upsized 8.8 million unit offering for gross proceeds of $197,560,000.</li>
<li>
		Cabelas Inc (NYSE: <a class="ticker" href="/stock/cab#NYSE">CAB</a>) fell 3.7 percent to $46.75 after the company reported weak results for its fourth quarter.</li>
</ul>